Get the Stockscreener App
10.10
2.02%
0.20
After Hours:
9.85
-0.25
-2.48%
Biomea Fusion Inc stock is traded at $10.10, with a volume of 1.11M.
It is up +2.02% in the last 24 hours and up +37.79% over the past month.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
See More
Previous Close:
$9.90
Open:
$9.88
24h Volume:
1.11M
Relative Volume:
1.41
Market Cap:
$362.46M
Revenue:
-
Net Income/Loss:
$-117.26M
P/E Ratio:
-3.0422
EPS:
-3.32
Net Cash Flow:
$-99.96M
1W Performance:
+22.42%
1M Performance:
+37.79%
6M Performance:
-32.44%
1Y Performance:
-26.60%
1-Day Range:
$9.655
$10.45
1-Week Range:
$7.845
$12.01
52-Week Range:
$3.61
$22.74
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
900 MIDDLEFIELD ROAD, REDWOOD CITY
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
Biomea Fusion: Recent Rally May Not Last, Despite Upcoming Data Catalysts - Seeking Alpha
We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate - Simply Wall St
Biomea Fusion, Inc. (NASDAQ:BMEA) to Post Q1 2025 Earnings of ($0.82) Per Share, Capital One Financial Forecasts - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) to Post Q1 2025 Earnings of ($0.82) Per Share, Capital One Financial Forecasts - Defense World
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies - MSN
Biomea Fusion Sees Unusually Large Options Volume (NASDAQ:BMEA) - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Stock Rating Upgraded by RODMAN&RENSHAW - MarketBeat
Scotiabank raises Biomea Fusion target on clinical progress By Investing.com - Investing.com South Africa
Biomea Fusion stock boosted by clinical progress in diabetes treatmentTruist - Investing.com
Scotiabank raises Biomea Fusion target on clinical progress By Investing.com - Investing.com Canada
Biomea’s diabetes studies back in business as FDA lifts hold - BioWorld Online
Wall Street SWOT: Biomea Fusion stock faces hurdles amid diabetes drug setback - Investing.com
Scotiabank raises Biomea Fusion target on clinical progress - Investing.com
Piper Sandler maintains Overweight on Biomea Fusion - Investing.com
Biomea Fusion PT raised by analysts as FDA lifts clinical holds for trials - Investing.com
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate - AOL
Biomea upgraded by analysts after FDA lifts clinical hold (NASDAQ:BMEA) - Seeking Alpha
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate - Yahoo Finance
IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday - MSN
Scotiabank raises Biomea Fusion target on clinical progress By Investing.com - Investing.com UK
Biomea Fusion (NASDAQ:BMEA) Price Target Raised to $9.00 - MarketBeat
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials - Yahoo Finance
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials - Pharmaceutical Technology
IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday - Benzinga
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies - Zacks Investment Research
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies - Yahoo Finance
Biomea Fusion (NASDAQ:BMEA) Stock Rating Upgraded by Truist Financial - MarketBeat
Biomea Fusion stock boosted by clinical progress in diabetes treatmentTruist - Investing.com India
Truist Securities Upgrades Biomea Fusion (BMEA) - MSN
US FDA lifts clinical hold on Biomea's diabetes trials after safety review - Reuters
US FDA lifts clinical hold on Biomea’s diabetes trials - WIBQ
US FDA lifts clinical hold on Biomea’s diabetes trials - WSAU
US FDA lifts clinical hold on Biomea’s diabetes trials - WNWN-FM
US FDA lifts clinical hold on Biomea’s diabetes trials - WKZO
Biomea stock jumps 9% after FDA lifts hold on Phase 1/2 study (NASDAQ:BMEA) - Seeking Alpha
Biomea Fusion upgraded to Buy from Neutral at Rodman & Renshaw - TipRanks
Biomea Fusion: FDA Lifts Hold on Diabetes-Treatment Trials - MarketWatch
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials - GlobeNewswire
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials - GlobeNewswire Inc.
DRW Securities LLC Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Bank of New York Mellon Corp Buys 29,400 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
(BMEA) Investment Report - Stock Traders Daily
Short Interest in Biomea Fusion, Inc. (NASDAQ:BMEA) Expands By 7.8% - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Update - MarketBeat
(BMEA) Investment Analysis - Stock Traders Daily
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Sees Large Decline in Short Interest - MarketBeat
Biomea Fusion, Inc. Expected to Post Q3 2024 Earnings of ($1.08) Per Share (NASDAQ:BMEA) - MarketBeat
Capital One Financial Comments on Biomea Fusion, Inc.’s Q3 2024 Earnings (NASDAQ:BMEA) - Defense World
iA Global Asset Management Inc. Acquires New Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):